Posted by Michael Wonder on 25 Jun 2021
Vericiguat approved in Japan to treat patients with chronic heart failure
23 June 2021 - Heart failure affects approximately 1.2 million people in Japan.
Bayer announced today that the Ministry of Health, Labour, and Welfare in Japan has approved soluble guanylate cyclase stimulator vericiguat under the brand name Verquvo.
Verquvo (vericiguat) 2.5 mg, 5 mg, and 10 mg is approved for the treatment of patients with chronic heart failure who are receiving standard treatment for chronic heart failure.
